在头颈癌手术中，多项研究证明了淋巴结产量 (LNY) 的预后意义。据我们所知，尚无综述评估 LNY 的影响因素及其对所有头颈鳞状细胞癌 (HNSCC) 亚部位生存结果的影响。根据系统性首选报告项目对 HNSCC 中的 LNY 进行了范围审查范围界定审查 (PRISMA-ScR) 框架的审查和荟萃分析扩展可回答以下研究问题：1) 哪些外科医生、病理学家和患者特征会影响 LNY？ 2) LNY 会影响哪些解剖亚部位的生存？外科医生的经验以及病理方案和人员的变化会影响 LNY。淋巴结清扫的范围、晚期肿瘤特征以及在学术机构的治疗与 LNY 增加有关。年龄 <40 岁、男性和 BMI > 30 等患者特征与 LNY 增加相关。在口腔中，LNY > 18 是改善总生存期 (OS)、无病生存期 (DFS) 和疾病特异性生存期 (DSS) 的独立预测因子。在口咽部，已发表的研究显示 LNY 对 OS、DFS 和 DSS 的影响结果不一。无论淋巴结阈值如何，LNY 与喉部的 OS 或 DFS 无关。提供者和患者特征可能会影响 LNY。 LNY ≥ 18 与口腔和 HNSCC 的整体生存获益相关。在 HNSCC 采用 LNY 作为质量指标之前，需要对 LNY 进行进一步研究，特别是在前瞻性临床试验中。版权所有 © 2024 作者。由爱思唯尔有限公司出版。保留所有权利。

In head and neck cancer surgery, several studies have demonstrated the prognostic significance of lymph node yield (LNY). To our knowledge, no review has evaluated both the contributing factors to LNY and its impact on survival outcomes across all head and neck squamous cell carcinoma (HNSCC) subsites.A scoping review of LNY in HNSCC was conducted according to The Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) framework to answer the following research questions: 1) Which surgeon, pathologist, and patient characteristics influence LNY? 2) Which anatomic subsites does LNY impact survival?Surgeon experience and variation in pathology protocols and personnel can impact LNY. Extent of nodal dissection, advanced tumor characteristics, and treatment at an academic facility are associated with increased LNY. Patient characteristics such as age <40, male gender, and BMI > 30 are associated with increased LNY. In the oral cavity, LNY > 18 is an independent predictor of improved overall survival (OS), disease free survival (DFS), and disease-specific survival (DSS). In the oropharynx, published studies show mixed results with regards to the impact of LNY on OS, DFS, and DSS. LNY has not been associated with OS or DFS in the larynx, irrespective of nodal threshold.Provider and patient characteristics may impact LNY. LNY ≥ 18 is associated with a survival benefit in the oral cavity and HNSCC overall. Further investigation of LNY particularly in prospective clinical trials is required prior to its adoption as a quality metric in HNSCC.Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.